AbbVie Inc (ABBV) Position Boosted by Griffin Asset Management Inc

Adjust Comment Print

It offers a line of products for maintenance, repair, remodeling, and decorating. The firm also provides reinsurance for mortality, morbidity, and lapse risk associated with products; and reinsurance for investment-related risks, as well as develops and markets technology solutions for the insurance industry. AbbVie Inc has a fifty-two week low of $61.30 and a fifty-two week high of $125.86. Overall, 14.12 Million shares exchanged hands versus its average volume of $12.59 Million. The institutional investor held 90,685 shares of the computer manufacturing company at the end of 2017Q3, valued at $14.24 million, up from 87,387 at the end of the previous reported quarter. During the same period in the prior year, the business posted $1.20 EPS. equities research analysts predict that AbbVie Inc will post 7.46 earnings per share for the current year. The stock, as of last close, traded 95.03% away to its 52 week low and was at a distance of -5.77% from its 52 week high. The shares were sold at an average price of $98.45, for a total value of $8,569,088.00. The Relative Volume value measured for AbbVie Inc. stands at 1.46. It has underperformed by 6.07% the S&P500. Thompson Siegel Walmsley Ltd Limited Liability Company has invested 0% in Westar Energy, Inc. Sheets Smith Wealth Mgmt owns 35,555 shares for 1.38% of their portfolio. The Massachusetts-based Putnam Investments Llc has invested 0.05% in the stock. Riggs Asset Managment Company, a Pennsylvania-based fund reported 46 shares.

The stock's short float is around of 1.09% and short ratio is 2.91. About 3.09M shares traded. Athenex, Inc. (NASDAQ:ATNX) has 0.00% since February 21, 2017 and is. It has underperformed by 16.70% the S&P500. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating, nine have given a buy rating and one has issued a strong buy rating to the stock. LOW was included in 9 notes of analysts from August 20, 2015. The rating was maintained by Citigroup with "Buy" on Friday, June 17. As per Monday, November 2, the company rating was upgraded by Morgan Stanley. The stock has a market cap of $188,350.00, a price-to-earnings ratio of 28.64, a price-to-earnings-growth ratio of 1.13 and a beta of 1.61. The firm has "Market Perform" rating given on Tuesday, January 26 by Cowen & Co. BMO Capital Markets downgraded shares of AbbVie from a "market perform" rating to an "underperform" rating and dropped their target price for the stock from $125.86 to $84.00 in a research note on Monday, January 29th. (NYSE:WR) earned "Buy" rating by J.P. Morgan on Tuesday, July 11. The firm has "Neutral" rating given on Friday, December 18 by Atlantic Securities. (NYSE:ABBV) to report earnings on April, 26.

Several analysts have recently issued reports on the company. This showed a surprise of 2.8% in the last quarter earnings. Ig Investment Management holds 0.64% or 2.73 million shares. ABBV's profit will be $2.83 billion for 16.84 P/E if the $1.78 EPS becomes a reality. The company reported $1.48 EPS for the quarter, topping the consensus estimate of $1.44 by $0.04. Therefore 24% are positive.

Sumitomo Mitsui Asset Management Company Ltd increased its stake in Hanesbrands Inc (HBI) by 274.76% based on its latest 2017Q3 regulatory filing with the SEC. As per Monday, October 16, the company rating was maintained by SunTrust. Jefferies maintained AbbVie Inc. (NYSE:ABBV) on Sunday, July 30 with "Hold" rating. Another trade for 10,325 shares valued at $250,536 was made by Marsh John T. on Monday, August 28. Deutsche Bank upgraded it to "Hold" rating and $88.0 target in Thursday, September 28 report. The rating was maintained by Goldman Sachs on Friday, March 10 with "Buy". Finally, Leerink Swann set a $106.00 target price on AbbVie and gave the company a "buy" rating in a report on Tuesday, December 5th. As per Wednesday, November 1, the company rating was maintained by Canaccord Genuity. (NYSE:WR) earned "Buy" rating by Evercore on Tuesday, July 11. As per Friday, September 11, the company rating was maintained by Brean Capital.

Since September 11, 2017, it had 0 insider purchases, and 5 selling transactions for $25.59 million activity.

According to the Recommendation Trends of the stock polled by Finviz, the company has a consensus recommendation of 2.4 out of the scale from 1 to 5, where 1 stands for Buy and 5 means Sell. South Street Advisors LLC's holdings in AbbVie were worth $14,475,000 as of its most recent SEC filing. (NYSE:ABBV) shares. The insider SALEKI-GERHARDT AZITA sold 8,300 shares worth $705,655. Private Capital Advisors Inc. now owns 41,620 shares of the company's stock worth $3,018,000 after buying an additional 145 shares during the period. (NYSE:ABBV) for 142,131 shares.

Investors of record on Friday, April 13th will be issued a $0.96 dividend. Its down 0.06, from 0.78 in 2017Q2.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company.

Zions Bancorporation raised its position in AbbVie Inc (NYSE:ABBV) by 110.2% during the third quarter, reports. Asset holds 0.91% of its portfolio in Facebook, Inc. Mountain Pacific Investment Advisers Id reported 9,678 shares stake. Mastrapasqua Asset Mgmt Incorporated holds 0.23% of its portfolio in AbbVie Inc. Palladium Partners LLC now owns 140,006 shares of the company's stock worth $10,152,000 after acquiring an additional 1,434 shares during the last quarter. Oregon Public Employees Retirement Fund reported 0.01% of its portfolio in Murphy USA Inc. Stevens First Principles Invest Advsr has invested 0% in AbbVie Inc. Bollard Grp Limited Liability accumulated 3,781 shares. Howe Rusling Inc holds 1.97% in AbbVie Inc. Wealthtrust Fairport Ltd Liability Com invested 1.07% of its portfolio in AbbVie Inc. AbbVie Inc. (ABBV)'s value Change from Open was at 2.92% with a Gap of 0.29%. Alley Lc reported 42,086 shares. Manufacturers Life The stated it has 3.19M shares. (NYSE:WR). Magellan Asset reported 94,986 shares stake.